Neuland Laboratories Limited

BSE:524558 Stock Report

Market Cap: ₹81.6b

Neuland Laboratories Past Earnings Performance

Past criteria checks 6/6

Neuland Laboratories has been growing earnings at an average annual rate of 52.8%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 16.5% per year. Neuland Laboratories's return on equity is 23.4%, and it has net margins of 19.3%.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate16.5%
Return on equity23.4%
Net Margin19.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Neuland Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524558 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2415,5863,0012,5710
31 Dec 2315,8093,1712,4490
30 Sep 2314,5742,6622,3080
30 Jun 2313,3332,1542,1420
31 Mar 2311,9151,6352,0260
31 Dec 2210,4061,0081,9690
30 Sep 2210,0788311,9340
30 Jun 229,7206511,8840
31 Mar 229,5176381,8320
31 Dec 219,4005931,8260
30 Sep 219,4897311,7250
30 Jun 219,3247421,5890
31 Mar 219,3708061,5050
31 Dec 208,8525401,4000
30 Sep 208,4363841,3310
30 Jun 207,8842571,2920
31 Mar 207,6401621,2420
31 Dec 197,4433211,2160
30 Sep 197,1202571,1920
30 Jun 196,9452161,1550
31 Mar 196,6751641,1300
31 Mar 185,2841211,0550
31 Mar 175,7894691,0100
31 Mar 165,1002738470
31 Mar 154,6921596450
31 Mar 144,657268815108
31 Dec 134,61925871290

Quality Earnings: 524558 has high quality earnings.

Growing Profit Margin: 524558's current net profit margins (19.3%) are higher than last year (13.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524558's earnings have grown significantly by 52.8% per year over the past 5 years.

Accelerating Growth: 524558's earnings growth over the past year (83.5%) exceeds its 5-year average (52.8% per year).

Earnings vs Industry: 524558 earnings growth over the past year (83.5%) exceeded the Pharmaceuticals industry 18%.

Return on Equity

High ROE: 524558's Return on Equity (23.4%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.